Oxagen Limited is a biopharmaceutical company developing novel small molecule drugs addressing asthma and other chronic allergic conditions. Its drug development programs target the CRTH2 receptor - a GPCR with a strong genetic association with asthma that plays a pivotal role in the initiation and maintenance of allergic conditions.

The Company’s most advanced drug candidate OC000459 is a once-daily oral CRTH2 antagonist in Phase IIb clinical development that has shown excellent efficacy in allergic asthmatics along with an excellent safety profile. It has also achieved clinical proof-of-concept in allergic rhinitis and allergic conjunctivitis. OC000459 is being developed to provide prescribers with a new, oral non-steroid option for allergic asthmatics that addresses co-morbid allergic conditions and has particular utility in younger patients.

Oxagen has an experienced management team with extensive combined experience in senior positions in top ten pharmaceutical companies. The team has proven ability in drug discovery, clinical development and drug registration and has prosecuted therapeutic targets from discovery to market across a range of therapeutic areas, but with particular expertise in inflammation and asthma. The company has driven its lead small molecule CRTH2 antagonist programme from concept through drug discovery and 14 clinical trials. The team has focused on building key external partnerships to facilitate fast, efficient development and will put in place partnerships to achieve commercialisation of its drug candidates. The Company is located in the UK and is based at Milton Park, south of Oxford.

Please click here for the company factsheet